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Abstract
Urothelial bladder carcinoma (UBC), the most frequent type (90%) of bladder cancer and 
the second most common malignancy of the urogenital region, is a relatively well under-
stood type of cancer, with numerous studies concerning pathogenetic pathways, natural 
history and bladder tumor biology being reported. Despite this, it continues to remain a 
FKDOOHQJHLQWKHRQFRORJ\ÀHOGPRVWO\GXHWRLWVUHODSVLQJDQGSURJUHVVLYHQDWXUHDQGWR
the heterogeneity in the response to cisplatin-containing regimens. Although the formulae 
based on clinical staging and histopathological parameters are classically used as diag-
QRVWLFDQGSURJQRVWLFWRROVWKH\KDYHSURYHQLQVXIÀFLHQWWRFKDUDFWHUL]HWKHLQGLYLGXDO
biological features and clinical behaviour of the tumours. Understanding the pathobiology 
of the disease can add important information to these classical criteria, and contribute 
to accurately predict outcome and individualize therapy for UBC patients. In this line of 
investigation, we found that tumour angiogenesis and lymphangiogenesis, the process of 
invasion and metastasis and the energy metabolism reprogramming / tumour microenvi-
URQPHQWHQFRPSDVVVHYHUDOSRWHQWLDOELRPDUNHUVWKDWVHHPWRLQÁXHQFHEODGGHUFDQFHU
aggressiveness and chemoresistance. We particularly highlight the roles of lymphovascular 
invasion, and of RKIP, CD147 and MCT1 immunoexpressions, as relevant prognostic and/or 
predictive biomarkers, and as promising areas of therapeutic intervention, eliciting for the 
development of additional studies that can validate and further explore these biomarkers.
© 2015 Associação Portuguesa de Urologia. Published by Elsevier España, S.L.U. This is 
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/)
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Introduction
Thirteen years ago, Hanahan and Weinberg suggested that, 
although encompassing variable mechanistic strategies, 
cancers in general acquire a set of functional biological ca-
pabilities during their multistep development. These in-
clude sustaining proliferative signaling, evading growth 
suppressors, resisting cell death, enabling replicative im-
mortality, inducing angiogenesis, and activating invasion 
and metastasis.1 In their recent review, the authors added 
to their previous model two enabling characteristics and 
two emerging hallmarks. They considered that genome in-
stability generates the genetic diversity underlying the ac-
TXLVLWLRQRIDOOKDOOPDUNVDQGWKDWLQÁDPPDWLRQSURPRWHV
multiple hallmark functions. Additionally, the establish-
ment of a tumour microenvironment by the malignant cells 
but also by recruited normal cells importantly contributes 
to energy metabolism reprogramming and immune destruc-
tion evasion in order to effectively support neoplastic pro-
liferation.2 This molecular knowledge is already being ap-
plied into clinical practice, with targeted therapies that 
interfere with each of the hallmarks being developed and 
entering in clinical trial phase or, in some cases, being ap-
proved for clinical use in treating certain forms of human 
cancer.3-5
In urothelial bladder cancer (UBC) setting, although a 
reasonable number of biomarkers seem to be prognostically 
relevant,6,7 there is a substantial delay in the translation 
into the clinics, and clinical trials with molecularly targeted 
agents have been few in number and largely unsuccessful.8,9 
This is probably due to the unique complexity involved in 
the dual-track pathway of bladder carcinogenesis, which 
postulates that UBC develops via two distinct but somewhat 
overlapping pathways, resulting in two main phenotypic 
variants with different biological behaviours and progno-
ses.10 However, areas in which biomarkers may prove valu-
able are evident, encompassing the three most important 
risk factors that threaten survival and life quality of bladder 
cancer patients.7 First, the majority of UBCs emerge as 
non-muscle invasive (NMI), low grade, papillary lesions. Due 
to their high risk of recurrence, current guidelines recom-
mend intense follow-up that classically relies on invasive 
WHFKQLTXHV VXFKDV F\VWRVFRS\DQGELRSV\ FDXVLQJ VLJQLÀ-
cant patient discomfort and implicating substantial costs. 
Thus, prediction of tumour recurrence through non-invasive 
methods would be of great value.11 Second, an important 
proportion of NMI tumours, such as high grade or carcinoma 
in situ lesions, incur at an increased risk of progression to 
muscle-invasive (MI) disease. Timely prediction of progres-
sion would guide a vigilant surveillance, and would help cli-
nicians to identify patients in need of early, aggressive man-
agement, while avoiding over-treatment in others.12 Third, 
the risk of metastasis is the main pitfall for MI-UBC patients, 
and the majority of bladder cancer deaths occur as a conse-
quence of metastatic disease.13 Although cisplatin-contain-
ing chemotherapy is recommended for locally-advanced or 
metastatic UBC,14 VXUYLYDO EHQHÀWV DUH LPSDLUHG LQ XS WR
50% of the patients due to chemoresistance and patient fra-
gility.15 In this scenario, robust biomarkers could help to 
identify circulating or lymph-node occult micrometastases, 
Características biológicas do carcinoma urotelial da bexiga: à descoberta de potenciais 
biomarcadores
Resumo
O carcinoma urotelial da bexiga (CUB), o tipo de cancro mais frequente deste órgão (90%) 
e o segundo mais comum da região genitourinária, está relativamente bem caracteriza-
do, fundamentado por inúmeros estudos sobre vias patogenéticas, histogénese e biologia 
WXPRUDO1RHQWDQWRSHUPDQHFHFRPRXPGHVDÀRQDRQFRORJLDSULQFLSDOPHQWHGHYLGRj
VXDHOHYDGDWD[DGHUHFLGLYDHSURJUHVVmRHjKHWHURJHQHLGDGHQDUHVSRVWDDWUDWDPHQ-
tos de quimioterapia contendo cisplatina. As fórmulas baseadas no estadiamento tumoral 
e em parâmetros histopatológicos, embora geralmente utilizadas como ferramentas de 
GLDJQyVWLFRHSURJQyVWLFRVmRLQVXÀFLHQWHVSDUDFDUDFWHUL]DUDVSURSULHGDGHVELROyJLFDV
e o comportamento clínico dos tumores. A compreensão detalhada da patobiologia da 
doença poderá adicionar informações importantes aos critérios clássicos, e contribuir 
para uma correta previsão individual do prognóstico e da terapêutica a utilizar nos doen-
tes com CUB. Nesta linha de investigação, o nosso grupo sugere que na angiogénese e na 
linfangiogénese tumoral, no processo de invasão e metastização e na reprogramação do 
metabolismo energético / microambiente tumoral estão implicados potenciais biomar-
FDGRUHVTXHSDUHFHPLQÁXHQFLDUDDJUHVVLYLGDGHWXPRUDOHDUHVLVWrQFLDjTXLPLRWHUDSLD
no CUB. Salienta-se o papel da invasão linfovascular, e da imunoexpressão das moléculas 
5.,3&'H0&7FRPRELRPDUFDGRUHVGHSURJQyVWLFRHRXSUHGLWLYRVGHUHVSRVWDj
terapêutica, e como áreas promissoras de intervenção terapêutica. É urgente desenvol-
ver estudos adicionais que continuem a explorar e, eventualmente, validar as potencia-
lidades destes biomarcadores.
© 2015 Associação Portuguesa de Urologia. Publicado por Elsevier España, S.L.U. Este 
é um artigo Open Access sob a licença de CC BY-NC-ND (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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could represent potential therapeutic targets, and could 
forecast and stratify responses to conventional cytotoxic 
therapies or to emerging targeted therapies (the so called 
companion biomarkers).9,16-18 Hence, UBC represents a con-
siderable opportunity and challenge for biomarkers’ re-
search.
In the last years, efforts have been taken to uncover 
prognostic and/or predictive biomarkers that might be use-
ful in the clinical care of UBC patients. Traditional ap-
SURDFKHVRIVLQJOHPROHFXOHRUVLQJOHSDWKZD\SURÀOLQJDUH
being replaced by investigations on panels of biomarkers 
encompassing several hallmarks of cancer.7,19,20 While the 
few biomarkers of potential clinical relevance that have 
EHHQLGHQWLÀHGVRIDUDUHPDLQO\UHODWHGWRWKHNH\PROHF-
XODUSDWKZD\VRIEODGGHUWXPRXULJHQHVLV>HJ)*)5ÀEUR-
blast growth factor receptor 3) and TP53 (tumour protein 
p53) mutations],6,7,21 there is the need to expand the re-
search into poorly explored scenarios of the malignant phe-
notype, in an attempt to unveil novel promising markers 
that can be integrated into a molecular signature with ac-
curate prognosis and predictive power. A cancer-related 
biomarker must be a molecule produced by the tumour, de-
tectable and measurable in patient specimens (tissue, 
blood or urine), representative of various tumour proper-
WLHVDQGUHSURGXFLEOHVSHFLÀFDQGVHQVLWLYH7,22 Several re-
cent reviews have explored the most promising UBC bio-
markers, although, to date, no biomarker panel has reached 
validation for daily clinical practice.6,7,21,23 Immunohisto-
chemical approaches in tissue arrays are well suited for the 
detection task, by being practical methods that can easily 
allow the translation of new described biomarkers into clin-
ical practice.24 In this line of investigation, our group used 
immunohistochemistry to study, in a cohort of well-charac-
WHUL]HG 8%& VDPSOHV WKH FOLQLFDO DQG SURJQRVWLF VLJQLÀ-
cance of several poorly studied putative biomarkers encom-
passing and overlapping three hallmarks of cancer: inducing 
tumour angiogenesis (and lymphangiogenesis), activating 
invasion and metastasis, and reprogramming cellular ener-
getics and the tumour microenvironment. We additionally 
performed validation assays with bladder cancer cell lines. 
2XU UHVHDUFK HIIRUWV KDYH UHVXOWHG LQ LPSRUWDQW ÀQGLQJV
FRQFHUQLQJVRPHELRORJLFDOSDUDPHWHUVWKDWVHHPWRLQÁX-
ence bladder cancer aggressiveness and chemoresistance. 
In the next sections, we will explore the state of the art of 
these evolving hallmarks, and provide our contribution in 
unveiling potential prognosis and predictive biomarkers, as 
well as new therapeutic targets, also reviewing the contri-
bution of other authors to the current knowledge on this 
ÀHOG
Tumour angiogenesis and lymphangiogenesis
The dissemination of malignant cells to distant organs from 
the primary tumour is the leading cause of mortality from 
cancer and, with few exceptions, all cancers can metasta-
size.25,26 Although metastasis can occur by local tissue inva-
sion and direct seeding of body cavities, the main routes of 
dissemination are the hematogenous and lymphogenous 
spread. Preclinical and clinical studies suggest that the lym-
phatic vascular system is preferred over the blood vascular 
system, and occurrence of lymph node metastasis is an im-
portant factor for patients’ prognosis and treatment deci-
sion-making.27,28 The malignant cells exploit both vascular 
systems by expressing growth factors that alter the normal 
pattern of blood and lymphatic vessel growth, creating con-
duits for metastasis to occur by tumour-induced angiogene-
sis and lymphangiogenesis.29
The overexpression of angiogenic and lymphangiogenic 
JURZWKIDFWRUVLQWXPRXUVVLJQLÀFDQWO\LQFUHDVHVEORRGYHV-
sel density (BVD) and lymphatic vessel density (LVD), and 
establishes the routes for blood vessel invasion (BVI) and 
O\PSKDWLFYHVVHOLQYDVLRQ/9,E\PDOLJQDQWFHOOV$VLJQLÀ-
FDQW QXPEHU RI UHWURVSHFWLYH VWXGLHV UHSRUWHG VLJQLÀFDQW
associations between the occurrence of angiogenesis and 
BVI, lymphangiogenesis and LVI, and the risk of tumour re-
currence, progression, lymph node metastasis, distant me-
tastasis and death for distinct cancer patients.29,30 Blocking 
the expression of angiogenic and lymphangiogenic growth 
factors in preclinical models has inhibited tumour growth 
and expansion of the tumour-associated vasculature, and 
reduced malignant spread.31,32 Therefore, it is not surprising 
that novel anti-angiogenic/lymphangiogenic agents and 
combinations including chemotherapeutic drugs, as well as 
targeted inhibitors, are currently under clinical trial phase 
or have already obtained the approval from the Food and 
Drug Administration for treating cancer patients.
Similarly to other types of cancer, the role of angiogene-
sis in UBC is well established. Both VEGF (vascular endothe-
lial growth factor) levels and high BVD counts independent-
ly predicted progression and lymph node metastasis, 
VLJQLÀFDQWO\ ORZHULQJ VXUYLYDO UDWHV33-35 Large scale ap-
SURDFKHVKDYHDOVRFRQÀUPHG9(*)DVDQLQGHSHQGHQWSURJ-
nosis factor.36 Moreover, although studies on lymphangio-
genesis occurrence and its usefulness in urothelial 
malignancies are fewer in number, the general tendency 
points out for an important task of lymphatic vessel forma-
tion in malignant dissemination.37,38 VEGF-C levels were as-
sociated with high lymphatic vessel density (LVD) counts, 
predicting lymph node metastasis.38,39 Both blood and lym-
phatic vessels participate in the metastatic cascade, and 
O\PSKRYDVFXODULQYDVLRQ/,KDVEHHQLGHQWLÀHGDVDQLQGH-
pendent prognostic factor for recurrence and overall surviv-
al.40 Importantly, it has been demonstrated that the LI sta-
tus helps to stratify N0 UBC patients who are at increased 
risk of bladder cancer recurrence and death.41 Despite 
these important associations, LI occurrence is not routinely 
described on the pathology reports, due to the lack of diag-
nosis reproducibility.42,43
In our research, we assessed angiogenesis, lymphangio-
genesis and lymphovascular invasion occurrence in 83 UBC 
tissue sections, using an immunohistochemical method to 
differentiate between blood and lymphatic endothelial 
cells44 (Table 1). We did observe that tumour neovascular-
ization occurrence (Figs. 1A and 1B) determines bladder 
FDQFHU DJJUHVVLYHQHVV DOWKRXJK QR VLJQLÀFDQW DVVRFLDWLRQ
with outcome variables was found. While contradicting a 
few prior reports,34,35 others have also failed to demonstrate 
correlations among BVD and prognosis,45 and it has been 
advocated that, due to the inconsistency among various 
studies, BVD alone does not capture the real effect of an-
giogenesis occurrence on tumour progression and metasta-
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sis.21 On the other hand, in our study it was noted that in-
tratumoural lymphatic vessels, described as collapsed and 
non-functional by some authors,46,47 had visible lumens in a 
VLJQLÀFDQWSURSRUWLRQRIFDVHVDQGQRHGHPDZDVREVHUYHG
ZKLFKVXSSRUWVDQHIÀFLHQWO\PSKDWLFÁRZ)LJ%0RUH-
over, these intratumoural vessels, when functional, seem to 
actively cooperate in malignant dissemination, as observed 
by the presence of single malignant cells in the well-pre-
served intratumoural lymphatic vessels (Fig. 1D), which 
portended a low overall survival rate. Similar results have 
been obtained by others.48$GGLWLRQDOO\WKHVSHFLÀFVWDLQLQJ
RIEORRGDQGO\PSKDWLFHQGRWKHOLXPVLJQLÀFDQWO\FRQWULEXW-
ed to an accurate evaluation of LI occurrence, and to a 
VSHFLÀFGLVWLQFWLRQEHWZHHQ%9,DQG/9,)LJV&DQG'
This was particularly important in the accurate detection of 
isolated malignant cells invading lymphatic capillaries, 
which have a higher propensity to survive in the lymphatic 
ÁRZZKHQFRPSDULQJZLWKWKHULJRUVRIWKHEORRGFLUFXOD-
tion. In fact, malignant emboli – easily detectable in hema-
toxylin and eosin (H&E) stained sections if no stromal re-
traction is observed – are more prone to invade the chaotic 
and hyperpermeable structure of the blood vasculature and 
WRRYHUFRPHWKHKRVWLOLWLHVLQKHUHQWWREORRGÁRZVXFKDV
serum toxicity, high shear stress and mechanical deforma-
tion.49&RQYHUVHO\O\PSKÁRZVVORZO\DQGKDVDFRPSRVL-
WLRQVLPLODUWRLQWHUVWLWLDOÁXLGEHLQJLGHDOIRUWKHVXUYLYDO
and dissemination of single malignant cells.50 These are 
PRUHGLIÀFXOWWRGHWHFWLQ+	(VHFWLRQV7KXVWKHVSHFLÀF
staining of lymphatic endothelium contributes to accurate-
O\GLDJQRVH/9,RFFXUUHQFH)LJ'ZKLFKVLJQLÀFDQWO\LP-
pairs overall survival, as well as BVI by malignant emboli 
)LJ&%9,ZDVLGHQWLÀHGDVDQLQGHSHQGHQWSURJQRVWLF
factor in our cohort. In another study where we developed 
a model of bladder cancer aggressiveness by the combined 
analysis of clinicopathological – stage and grade – and bio-
ORJLFDO²VSHFLÀFDOO\KLJKOLJKWHG%9,DQG/9,DQG&'H[-
pression – parameters51 (Table 1), we found that BVI and LVI 
clearly contributed to separate between low and high ag-
gressiveness groups. BVI and LVI occurrence may, therefore, 
represent potential prognostic biomarkers that can guide 
SHUVRQDOL]HG VHOHFWLRQ RI SDWLHQWV OLNHO\ WR EHQHÀW IURP
perioperative chemotherapy regimens and/or targeted 
therapies. In accordance, a recent review has emphasized 
that LI should be routinely reported in the pathological re-
SRUWDQGWKDWLPPXQRKLVWRFKHPLVWU\LGHQWLÀFDWLRQRIEORRG
and lymphatic vessels should be employed in histologically 
HTXLYRFDOFDVHVIRUFRQÀUPDWLRQ43
Angiogenesis and lymphangiogenesis represent potential 
targets for therapeutic intervention in the UBC setting, and 
several compounds targeting the most relevant neovascu-
larization signalling pathways are being tested in clinical 
trials.52 However, caution is recommended, due to the risk 
of refractoriness to VEGFs/VEGFRs signalling blockade.53 In 
fact, compensation mechanisms to VEGF abrogation in UBC 
cells lines have been described.54 In alternative, the mam-
malian target of rapamycin (mTOR) intracellular pathway, 
besides transducing signals that activate the translational 
machinery and promote cell growth,55 is also an important 
signalling mediator in hypoxia-induced angiogenesis.56 Some 
rapamycin analogues have demonstrated anti-angiogenic 
Table 1 Selected studies on urothelial bladder cancer biomarkers.
Markers Cohort n 0DMRUÀQGLQJV Ref
BVD RC 83 /9'DVVRFLDWHGZLWKWXPRXUDJJUHVVLYHQHVV,GHQWLÀFDWLRQRI/,ZDV
VLJQLÀFDQWO\LPSURYHGZKHQXVLQJYHVVHOPDUNHUV%9,DQG/9,VLJQLÀFDQWO\
lowered DFS and OS. BVI remained as an independent prognostic factor for OS
44
LVD
BVI
LVI
p-mTOR RC 76 p-mTOR expression decreased with increasing stage, and was lost from 
QRQWXPRXUWRWXPRXUXURWKHOLXPS7S7SRVLWLYHFDVHVKDGDVLJQLÀFDQW
worse DFS rate
61
RKIP RC 81 5.,3H[SUHVVLRQDVVRFLDWHGZLWKDIDYRXUDEOHFOLQLFRSDWKRORJLFDOSURÀOH/RVV
RI5.,3H[SUHVVLRQDVVRFLDWHGZLWK/9,RFFXUUHQFHDQGVLJQLÀFDQWO\ORZHUHG
DFS and OS, remaining as an independent prognostic factor for DFS
66
MCT1  
MCT4  
CD147
RC and TUR 114 0&70&7DQG&'H[SUHVVLRQVVLJQLÀFDQWO\DVVRFLDWHGZLWKXQIDYRUDEOH
clinicopathological parameters and poor prognosis. In selected platinum 
WUHDWHGSDWLHQWV26ZDVVLJQLÀFDQWO\ORZHUIRUWKRVHZLWK0&7&'
positive tumours
71
Scoring 
model*
RC 77 The model was stronger in predicting prognosis than the individual 
parameters, remaining as an independent prognostic factor for DFS and OS. 
&'H[SUHVVLRQDGGHGVLJQLÀFDQWSURJQRVWLFLQIRUPDWLRQWRWKHPRGHO
51
BVD: blood vessel density; BVI: blood vessel invasion; DFS: disease-free survival; LVD: lymphatic vessel density; LVI: lymphatic vessel 
invasion; LI: lymphovascular invasion; MCT: monocarboxylate transporter; OS: overall survival; p-mTOR: phospho-mammalian target of 
rapamycin; RC: radical cystectomy; RKIP: Raf kinase inhibitor protein; TUR: transurethral resection.
* Scoring model: includes clinicopathological parameters – stage and grade – combined with three biological parameters – BVI, LVI and 
CD147 overexpression.
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effects in UBC pre-clinical57 and clinical trials.58 Neverthe-
less, the levels of mTOR activation in UBC tissue sections 
have been poorly explored, and controversial results were 
found.59,60 We assessed phospho-mTOR (p-mTOR) levels in a 
series of 76 UBC sections with representative tumour and 
non-tumour (normal-like or hyperplasic) areas, where blood 
and lymphatic vessels were also stained by immunohisto-
chemistry, in order to correlate angiogenesis and lymphan-
giogenesis occurrence with p-mTOR expression61 (Table 1). 
1RVLJQLÀFDQWDVVRFLDWLRQVZHUHIRXQGEHWZHHQWKHFOLQLFR-
pathological parameters and vascular density, and p-mTOR 
expression. Even though, we observed that p-mTOR de-
creased with increasing stage, and was lost from non-tu-
mour to tumour urothelium, particularly in MI lesions, 
where immunoexpression was observed in a few spots of 
cells. Angiogenesis occurrence was impaired in pT3/pT4 
negative tumours; conversely, pT3/pT4 positive cases had 
worse survival rates, as reported by other authors.59 In NMI 
tumours, p-mTOR was evenly distributed within the malig-
nant urothelium, although staining was stronger at the su-
SHUÀFLDOOD\HUVRIFHOOV)LJ$UHVHPEOLQJWKHSDWWHUQRI
expression that was observed in the non-tumour urotheli-
um, where p-mTOR expression was restricted to umbrella 
FHOOV DQG VRPH VXSHUÀFLDO FHOOV RI WKH LQWHUPHGLDWH OD\HU
(Fig. 2B). This pattern of expression has been similarly de-
scribed in other studies.59 We hypothesized that umbrella 
cells from non-tumour urothelium express p-mTOR consti-
tutively, as part of their metabolic plasticity, and that NMI 
lesions with increasing malignant potential extend immuno-
expression to the inner layers. The two patterns among MI 
tumours – absence of expression or expression in cell clus-
ters – probably indicate divergent biological scenarios en-
compassing the mTOR pathway. Additional studies with 
larger and more comprehensive UBC series and panels of 
mTOR upstream and downstream effectors, together with 
reproducible immunohistochemical and molecular ap-
proaches, and with in vivo and in vitro bladder tumour 
models, are urgently needed to clarify the backstage of the 
mTOR pathway in human urothelial bladder cancer, in order 
to expedite the research on potential target therapeutic 
approaches.
Invasion and metastasis
Tumour metastasis, the most fearsome aspect of cancer, is 
a multistage process during which malignant cells separate 
from the primary tumour and invade discontiguous organs. 
Angiogenesis and lymphangiogenesis, as already mentioned, 
are essential for invasion and metastasis to occur, but nu-
merous additional events are also necessary for the success 
of the metastatic spread. In fact, a long series of sequen-
tial, rate limiting, interrelated steps must occur, involving 
the physical translocation of a malignant cell to a distant 
organ, and the ability of that cell to develop into a meta-
VWDWLFOHVLRQDWWKHGLVWDQWVLWH7KHÀQDOUHVXOWGHSHQGVQRW
only on the intrinsic properties of the tumour cells, but also 
on the host responses.62
+LJKULVN10,DQGPRUHRIWHQ0,8%&FDUU\DVLJQLÀ-
cant threat of invasion and metastasis despite radical sur-
gical treatment.13 Timely detection of biomarkers that en-
able malignant cells with invasive and metastatic properties 
ZRXOG DOORZ LGHQWLI\LQJ SDWLHQWV WKDW FRXOG EHQHÀW IURP
early aggressive approaches such as radical cystectomy and 
perioperative chemotherapy, and would guide the develop-
ment of targeted therapies. Conversely, while inhibiting 
Figure 1 CD31 and D2-40 immunoexpressions in urothelial 
bladder carcinoma. Intratumoral blood vessels highlighted by 
&' $ùDPSOLÀFDWLRQDQG&ùDPSOLÀFDWLRQDQG
intratumoral lymphatic vessels highlighted by D2-40 (B and D, 
ùDPSOLÀFDWLRQLQLQYDVLYHXURWKHOLDOFDUFLQRPD(YLGHQFH
of internal negative control in B (* D2-40 negative blood ves-
sel). A small malignant embolus and an isolated malignant cell 
are invading intratumoral blood (C) and lymphatic (D) vessels 
(adapted from Afonso et al.44).
Figure 2 p-mTOR immunoexpression in normal and malignant 
urothelium. A, non-muscle invasive papillary tumour expressing 
F\WRSODVPLFSP725LQDKHWHURJHQHRXVSDWWHUQùDPSOLÀ-
cation), with the luminal and intermediate cell layers being 
more intensely stained than the layer of basal cells. B, normal 
XURWKHOLXPùDPSOLÀFDWLRQH[KLELWLQJF\WRSODVPLFSP725
LPPXQRH[SUHVVLRQUHVWULFWHGWRWKHVXSHUÀFLDOOD\HUVDGDSWHG
from Afonso et al.61).
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The biological mechanisms that reprogram cellular ener-
getics and model the tumour microenvironment are poorly 
characterized in bladder cancer. Thus, we elected a panel 
of three microenvironment-related molecules and investi-
gated their expressions in a subset of tumour tissue sec-
tions from 114 UBC patients treated by transurethral resec-
tion and/or radical cystectomy71 (Table 1). The central 
player was CD147, a tumor cell surface molecule implicat-
ed in extracellular matrix remodeling, angiogenesis and 
tumour growth, and related with chemoresistance-promot-
ing events.72 We had previously demonstrated the prognos-
tic impact of CD147 overexpression in bladder cancer pa-
tients, when we developed a model of UBC aggressiveness 
that included clinicopathological and biological parame-
ters51 (Table 1). In fact, CD147 expression was largely pre-
ponderant in the high aggressiveness group, and clearly 
added prognostic information to the model. For that rea-
son, we decided to re-evaluate this glycoprotein in a larger 
series, together with other molecular companions. Thus, 
we observed that CD147 was upregulated in bladder tu-
PRXUWLVVXH)LJ$VLJQLÀFDQWO\DVVRFLDWLQJZLWKDGLV-
PDO FOLQLFRSDWKRORJLFDO SURÀOH DQGSRRU SURJQRVLV2WKHU
DXWKRUVKDYHLGHQWLÀHG&'H[SUHVVLRQLQ8%&DVDQLQ-
dependent prognostic biomarker,73,74 and have additionally 
biomarkers of invasion and metastasis emerges as an at-
tractive therapeutic strategy, restoring the function of me-
tastasis suppressor proteins is not less appealing. In this 
scenario, the role of the metastasis suppressor RKIP (Raf 
kinase inhibitor protein) in cancer has been highlighted 
due to its ability to modulate several intracellular signal-
ling cascades involved in cell differentiation, cell cycle ki-
netics, apoptosis, epithelial to mesenchymal transition and 
cell migration.63 Given its pleiotropic abilities in maintain-
ing cellular equilibrium, it is not surprising that RKIP down-
regulation associates with metastatic events in an increas-
ing number of solid tumours.64 Its preponderance in UBC 
setting is largely unknown, although low mRNA levels have 
been reported in NMI tumours, when compared with nor-
mal urothelium.65
We evaluated RKIP expression in a cohort of 81 tumour 
sections from UBC patients. Blood and lymphatic vessels 
were also assessed, in order to correlate BVI and LVI occur-
rence with RKIP levels66 (Table 1). To the best of our knowl-
HGJH WKLVZDV WKHÀUVW VWXG\HYDOXDWLQJ5.,3 LPPXQRH[-
pression in bladder cancer tissue samples. We observed a 
homogeneous expression of RKIP in normal urothelium (Fig. 
3A) and in tumour sections with a favourable clinicopatho-
ORJLFDOSURÀOHQDPHO\10,WXPRXUVZKHUH/9,ZDVDEVHQW
(Fig. 3B). Conversely, a heterogeneous pattern of expres-
sion, with loss of RKIP expression intensity from the tumour 
centre to the invasion front, was associated with LVI occur-
UHQFH)LJ&0RUHRYHUORZ5.,3H[SUHVVLRQVLJQLÀFDQWO\
lowered disease-free and overall survival, remaining as an 
independent prognostic factor for disease-free survival. 
RKIP loss or diminution had been previously reported in oth-
HUW\SHVRIDJJUHVVLYHFDQFHUVVLJQLÀFDQWO\LPSDLULQJSURJ-
nosis. Clinically, RKIP expression is higher in benign tumors 
than in malignant tissues while its expression is completely 
absent in metastases.63 Additional studies in bladder cancer 
VHWWLQJQHHGWREHXUJHQWO\GHYHORSHGLQRUGHUWRFRQÀUP
our promising results and to expand the research into ther-
apeutic strategies that can potentially restore RKIP func-
tionality. Besides acting as a prognostic biomarker, RKIP 
status may also have a role as a predictive biomarker, once 
it has been demonstrated that its expression may potenti-
ate apoptosis induced by chemotherapeutic agents, which 
PLJKWEHXVHIXOLQGHÀQLQJWKHUDS\UHVSRQVHSURÀOHV67,68
Energy metabolism reprogramming  
and the tumour microenvironment
Altered energy metabolism, although only recently emerged 
as a new hallmark of cancer,2 is proving to be as widespread 
in tumour cells as the classical traits of malignancy. In fact, 
cancer growth is characterized by deregulated cell prolifera-
tion and corresponding adjustments of energy metabolism, 
such as the adoption of the Warburg effect. This necessarily 
involves different inputs to the tumour microenvironment, 
namely the extrusion of high amounts of lactate from the 
malignant cells that will sculpt an acid-resistant phenotype, 
which supports increased migration and invasion, favouring 
metastasis.69,70 Molecules and pathways involved in this intri-
cate backstage of malignancy potentially represent new ar-
eas of therapeutic intervention.
Figure 3 RKIP immunoexpression in normal and malignant 
urothelium. A, immunohistochemical positive reaction for RKIP 
LQ QRUPDO XURWKHOLXP ù DPSOLÀFDWLRQ % D QRQLQYDVLYH
papillary tumour showing a homogeneous pattern of expression 
ùDPSOLÀFDWLRQ&DQLQÀOWUDWLQJWXPRXUH[KLELWLQJDKHW-
erogeneous pattern, with the tumour core being more intense-
O\VWDLQHGWKDQWKHLQYDVLYHIURQWùDPSOLÀFDWLRQDGDSWHG
from Afonso et al.66).
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highly aggressive tumours (Fig. 4B and 4C), and MCT1 over-
expression impaired overall survival. In accordance, a re-
cent study demonstrated the independent prognostic signif-
icance of MCT1 and MCT4 in UBC77; their upregulation has 
also been observed in other malignancies.78 Interestingly, a 
&' DQG 0&7 GRXEOHSRVLWLYH SURÀOH ZDV VLJQLÀFDQWO\
associated with unfavourable clinicopathological parame-
ters and poor prognosis in our UBC series, and discriminated 
a poor prognosis group in cisplatin-treated patients. We hy-
pothesized that MCT1 cooperates with CD147 in the promo-
tion of a chemoresistance phenotype and, possibly, of other 
proposed it as a predictive biomarker in the setting of cis-
platin-containing regimens.74 7R FRQÀUP WKLV K\SRWKHVLV
we established four CD147-expressing UBC cell lines and 
studied the effect of cisplatin treatment on cell viability, 
cell cycle distribution and cell death, as well as on the 
migration and invasion abilities of the cells. CD147 expres-
sion was then downregulated in a cisplatin less-sensitive 
cell line (Fig. 5A). Importantly, we found that CD147 down-
regulation clearly increased chemosensitivity to cisplatin 
)LJ%7RWKHEHVWRIRXUNQRZOHGJHWKLVZDVWKHÀUVWin 
vitro study demonstrating that CD147 depletion in UBC 
cells enhances the therapeutic action of cisplatin, high-
lighting this molecule as a potential prognostic and predic-
tive biomarker. 
In order to further elucidate CD147 interactions, we also 
analyzed monocarboxylate transporter (MCT) expressions in 
the cohort of 114 UBC patients71 (Table 1). MCTs, particular-
ly MCT1 and MCT4, play a key role in the promotion of the 
hyper-glycolytic acid-resistant phenotype, by exporting lac-
tate from the glycolytic malignant cells to the tumour mi-
croenvironment.75 CD147 has been described as a chaper-
one for the proper expression of MCTs at the plasma 
membrane,76 and our results support that function. In fact, 
ZH IRXQG VLJQLÀFDQW DVVRFLDWLRQV DPRQJ0&70&7DQG
CD147 expressions. MCT1 and MCT4 were upregulated in 
Figure 4 CD147, MCT1 and MCT4 immunoexpressions in 
urothelial bladder carcinoma. Muscle-invasive tumours exhibit-
ing cytoplasmic and membrane immunoexpression of CD147 (A, 
ùDPSOLÀFDWLRQ0&7%ùDPSOLÀFDWLRQDQG0&7&
ùDPSOLÀFDWLRQLQWKHPDOLJQDQWXURWKHOLXPZLWKQHJDWLYH
stromas (adapted from Afonso et al.71).
CO
NT
RO
L
CD147
MCT1
MCT4
DAY 5
Ce
ll 
Vi
ab
ili
ty
 (%
)
Cisplatin (ug/ml)
siRNA scramble IC50: 24.11 ug/ml
siRNA CD147 IC50: 7.42 ug/ml
140
120
100
80
60
40
20
0
0 10 20 30 40 50 60 70 80 90 100
DAY 8 A
B
β-actin
SC
RA
M
BL
E
si
CD
14
7
SC
RA
M
BL
E
si
CD
14
7
Figure 5 Effect of CD147 downregulation in HT1375 cell line 
on the expression of MCTs and on chemosensitivity to cisplatin 
(treatment with cisplatin between days 5 and 8 after reverse 
transfection). A, CD147, MCT1 and MCT4 immunoexpressions in 
HT1376 control cells, and Western blot analysis of CD147, MCT1 
and MCT4 expressions in control/scramble HT1376 cells and in 
siCD147 HT1376 cells, showing that CD147 silencing was ac-
companied by a decrease in MCT1 and MCT4 expressions. B, 
effect of cisplatin on the viability of scramble and siCD147-
HT1376 cells, as detected by the MTS assay after 72 hours of 
treatment, showing that siCD147 cells were more sensitive to 
cisplatin (adapted from Afonso et al.71).
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logical problem, mostly due to its heterogeneous natural 
history and clinical behavior. Validated biomarkers would 
certainly help to elucidate unique biological features that 
may allow identifying patients who are at increased risk of 
recurrence, progression, metastasis and/or chemorefracto-
functions that are primarily attributed to CD147. In fact, it 
appears that CD147 maturation is affected by MCT expres-
sion.79 In our in vitro study, CD147 depletion was accompa-
nied by a marked decrease in the expression of MCT1 and 
MCT4 (Fig. 5A), which suggests CD147 as an MCT1/4 chaper-
one. It would be interesting to silence MCT1 expression in 
the UBC cell line and to study CD147 expression levels, in 
RUGHUWRFRQÀUPWKHRSSRVLWH
Overall, our results point out for an important role of 
CD147 and their companions in promoting a highly aggres-
sive phenotype where glycolysis is upregulated, contribut-
ing to acidify the tumour microenvironment, enabling the 
malignant cells with growth, migration, invasion and che-
moresistance abilities that can only be overcome if new 
approaches of target therapeutic intervention are investi-
gated.
The utility of combining distinct biomarkers – 
practical implications
Currently, there is no doubt that inclusion of prognostic and 
predictive biomarkers into the classical instruments of diag-
nosing the disease and predicting outcomes, such as risk 
VWUDWLÀFDWLRQWDEOHV80,81 nomograms82,83DQGDUWLÀFLDOQHXUDO
networks,84,85ZRXOGFHUWDLQO\UHÀQHGLDJQRVLVSURJQRVLVDQG
therapeutic decision, with several studies demonstrating the 
SRWHQWLDOLPSDFWRIGHYHORSLQJULVNVWUDWLÀFDWLRQWRROVWKDW
integrate clinicopathological and biological parameters.51,86,87 
Moreover, it seems that combining biomarkers inherent to 
different cancer hallmarks improves predictive accuracy 
over one biomarker abnormality, as several biomarkers may 
help to elucidate individual biological features of the tu-
mours.12,20,51,88-90 As it was previously mentioned, we devel-
oped a model of tumour aggressiveness by the combined 
analysis of two clinicopathological parameters – stage and 
grade – with three biological parameters – BVI, LVI and CD147 
overexpression51 (Table 1). Therefore, we included biomark-
ers that are mainly associated with angiogenesis (BVI), 
lymphangiogenesis (LVI), energy metabolism reprogramming, 
invasion and chemoresistance (CD147). The parameters in-
cluded in the model had individual prognostic impact on the 
77 UBC patients that were studied, as demonstrated in uni-
variate analysis. However, the model was stronger in pre-
dicting prognosis, clearly separating a low aggressiveness 
from a high aggressiveness group, and remaining as an inde-
pendent prognostic factor for disease-free (Fig. 6A) and 
overall survival (Fig. 6B). If an additional biomarker was in-
cluded in the model, namely immunoexpression of the me-
tastasis suppressor RKIP, its accuracy would be further en-
hanced (data not shown). Therefore, combining distinct 
biomarkers with the classical clinicopathological parameters 
will have undeniable impact for UBC patients, who may ben-
HÀWLQWKHIXWXUHIURPDFFXUDWHSUHGLFWLRQRIRXWFRPHVDQG
response to therapy, and guided targeted therapy. 
Conclusion
Bladder cancer, being the second most common malignancy 
RIWKHXURJHQLWDOUHJLRQUHSUHVHQWVDVLJQLÀFDQWHSLGHPLR-
Tumour Aggressiveness Scoring System
Su
rv
iva
l p
ro
ba
bi
lity
Survival time (months)
0-2 positive parameters (n=16)
3-5 positive parameters (n=42)
0-2 positive parameters-censored (n=14)
3-5 positive parameters-censored (n=5)
1,0
0,8
0,6
0,4
0,2
0,0
0
Log Rank: p<0.001
12 24 36 48 60 72 84 96 108 120
Tumour Aggressiveness Scoring System
0-2 positive parameters (n=14)
3-5 positive parameters (n=40)
0-2 positive parameters-censored (n=16)
3-5 positive parameters-censored (n=7)
Su
rv
iva
l p
ro
ba
bi
lity
1,0
0,8
0,6
0,4
0,2
0,0
Survival time (months)
B
0 12 24 36 48 60 72 84 96 108 120
Log Rank: p<0.001
A
Figure 6 Survival analysis of urothelial bladder cancer pa-
tients based on a tumour aggressiveness scoring system. 5-year 
disease-free survival (A) and 5-year overall survival (B) based 
on a tumour aggressiveness scoring system that includes T3/T4 
pathologic stage, grade III, occurrence of blood vessel invasion 
by malignant emboli, occurrence of lymphatic vessel invasion 
by isolated malignant cells and CD147 overexpression (n=77) 
(adapted from Afonso et al.51).
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ry relapse. In addition, biomarkers may improve prediction 
of response to therapy and guide us to a new era of tailored 
and targeted treatment. Current research efforts are di-
rected into the elaboration of nomograms that can combine 
well-established clinicopathological parameters with novel 
putative biomarkers. In this line of investigation, we sug-
gest that lymphovascular invasion occurrence, and RKIP, 
CD147 and MCT1 expressions might be relevant prognostic 
and/or predictive biomarkers, and promising areas of ther-
apeutic intervention, eliciting for the development of addi-
tional studies that can validate and further explore the po-
tentialities of our work. We additionally stand up for the 
VSHFLÀF VWDLQLQJ RI EORRG DQG O\PSKDWLF HQGRWKHOLXP E\
immunohistochemistry in histologically equivocal cases that 
UHTXLUHFRQÀUPDWLRQLQRUGHUWRLGHQWLI\LPDJHVRIO\PSKR-
vascular invasion that could be missed during the classical 
evaluation on H&E stained tumour sections, and to allow an 
accurate discrimination between the two forms of lympho-
vascular invasion. There is the urgent need to transpose 
these and other biomarker tests on small groups of patients 
to large-scale independent validation assays, encompassing 
multi-institutional collaborations, so that prospective vali-
dations and randomized trials based on the retrospective 
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